id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1977-N-0025-0003,FDA,FDA-1977-N-0025,FDA,Notice,NPR-Notice of Proposed Rule-Making,2002-08-28T04:00:00Z,2002,8,2002-08-28T04:00:00Z,2002-11-20T04:59:59Z,2008-07-14T18:31:49Z,,0,0,09000064805da2c2
FDA-1977-N-0025-0001,FDA,FDA-1977-N-0025,"Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over- the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph, and Related Labeling",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2002-08-28T04:00:00Z,2002,8,2002-08-28T04:00:00Z,2002-11-20T04:59:59Z,2019-02-22T02:03:59Z,02-21122,0,0,09000064805da214
FDA-1977-N-0025-0002,FDA,FDA-1977-N-0025,FDA,Notice,NPR-Notice of Proposed Rule-Making,2002-08-28T04:00:00Z,2002,8,2002-08-28T04:00:00Z,2002-11-20T04:59:59Z,2008-07-14T18:31:22Z,,0,0,09000064805da2c1
FDA-1977-N-0025-0004,FDA,FDA-1977-N-0025,FDA,Notice,NPR-Notice of Proposed Rule-Making,2002-08-28T04:00:00Z,2002,8,2002-08-28T04:00:00Z,2002-11-20T04:59:59Z,2008-07-14T18:32:53Z,,0,0,09000064805da2c3